Literature DB >> 10047455

Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines.

H Zhang1, P P Koty, J Mayotte, M L Levitt.   

Abstract

Tissue transglutaminase (tTG) and keratinocyte transglutaminase (kTG), as well as the cross-linked envelopes (CLE) that they form, have been associated with squamous differentiation and programmed cell death in epithelial cells. When interferon-beta (IFN-beta) was used to stimulate differentiation and programmed cell death in the human lung cancer cell lines NCI-H596 and NCI-H226, the cells underwent a decrease in cellular density. In NCI-H596 IFN-beta caused an increase in kTG activity and DNA fragmentation in the lower density cells, which were significantly slower growing than control cells. However, in the higher density cells, which were only slightly slower growing than control cells, IFN-beta caused an increase in tTG activity and CLE competence. Dual-parameter flow cytometry demonstrated that IFN-beta-induced squamous differentiation preceded programmed cell death. Treatment of NCI-H596 cells with monodansylcadaverine, a transglutaminase inhibitor, prevented the increase in CLE competence, but did not inhibit DNA fragmentation. These results suggest that IFN-beta can induce NCI-H596 cells to enter multiple cell death pathways and that these pathways are not only differentiation related, but may also be growth driven. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047455     DOI: 10.1006/excr.1998.4329

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  7 in total

1.  Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells.

Authors:  Carla Esposito; Monica Marra; Gaia Giuberti; Anna Maria D'Alessandro; Raffaele Porta; Anna Cozzolino; Michele Caraglia; Alberto Abbruzzese
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

2.  Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.

Authors:  Jennifer L Dembinski; Shanna M Wilson; Erika L Spaeth; Matus Studeny; Claudia Zompetta; Ismael Samudio; Katherine Roby; Michael Andreeff; Frank C Marini
Journal:  Cytotherapy       Date:  2013-01       Impact factor: 5.414

3.  Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics.

Authors:  Bei H Morrison; Joseph A Bauer; Jiadi Hu; Ronald W Grane; Aylin M Ozdemir; Mamta Chawla-Sarkar; Bendi Gong; Alex Almasan; Dhananjaya V Kalvakolanu; Daniel J Lindner
Journal:  Oncogene       Date:  2002-03-14       Impact factor: 9.867

4.  Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice.

Authors:  Takaya Matsuzuka; Raja Shekar Rachakatla; Chiyo Doi; Dharmendra Kumar Maurya; Naomi Ohta; Atsushi Kawabata; Marla M Pyle; Lara Pickel; Jennifer Reischman; Frank Marini; Deryl Troyer; Masaaki Tamura
Journal:  Lung Cancer       Date:  2010-10       Impact factor: 5.705

5.  Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31.

Authors:  Yijan E Chang; Loren Pena; Ganes C Sen; Jung K Park; Laimonis A Laimins
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Role of stem cells in cancer therapy and cancer stem cells: a review.

Authors:  Jayesh Sagar; Boussad Chaib; Kevin Sales; Marc Winslet; Alexander Seifalian
Journal:  Cancer Cell Int       Date:  2007-06-04       Impact factor: 5.722

7.  Human umbilical cord matrix-derived stem cells expressing interferon-β gene inhibit breast cancer cells via apoptosis.

Authors:  Ching-Ju Shen; Te-Fu Chan; Chien-Chung Chen; Yi-Chiang Hsu; Cheng-Yu Long; Chung-Sheng Lai
Journal:  Oncotarget       Date:  2016-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.